Global Clinical Oncology Next Generation Sequencing (NGS) Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 104

Report ID: 3262

NGS allows the testing of all types of variants including single-nucleotide variations, insertions, deletions, exon duplications, gene copy number changes and translocations.
The key factor contributing to the growth of the NGS market is the improved understanding of the genetic markers of virulence and resistance.
In 2018, the global Clinical Oncology Next Generation Sequencing (NGS) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Clinical Oncology Next Generation Sequencing (NGS) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Clinical Oncology Next Generation Sequencing (NGS) development in United States, Europe and China.

The key players covered in this study
Illumina
Roche
Agilent Technologies
Knome
Genomatix Software
GATC Biotech
Oxford Nanopore Technologies
Macrogen
Life Technologies
DNASTAR
Exosome Diagnostics
Biomatters
CLC Bio
BGI
Qiagen
Perkin Elmer
Pacific Bioscience
Partek
GnuBIO
Foundation Medicine
Paradigm
Caris Life Sciences
Myriad Genetics

Market segment by Type, the product can be split into
NGS Pre-Sequencing
Sequencing
NGS Data Analysis
Primary, Secondary & Tertiary Data Analysis

Market segment by Application, split into
Academic & Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Clinical Oncology Next Generation Sequencing (NGS) status, future forecast, growth opportunity, key market and key players.
To present the Clinical Oncology Next Generation Sequencing (NGS) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Clinical Oncology Next Generation Sequencing (NGS) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size Growth Rate by Type (2014-2025)
1.4.2 NGS Pre-Sequencing
1.4.3 Sequencing
1.4.4 NGS Data Analysis
1.4.5 Primary, Secondary & Tertiary Data Analysis
1.5 Market by Application
1.5.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Share by Application (2014-2025)
1.5.2 Academic & Clinical Research
1.5.3 Hospitals & Clinics
1.5.4 Pharma & Biotech Entities
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size
2.2 Clinical Oncology Next Generation Sequencing (NGS) Growth Trends by Regions
2.2.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Regions (2014-2025)
2.2.2 Clinical Oncology Next Generation Sequencing (NGS) Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Clinical Oncology Next Generation Sequencing (NGS) Market Size by Manufacturers
3.1.1 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue by Manufacturers (2014-2019)
3.1.2 Global Clinical Oncology Next Generation Sequencing (NGS) Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Clinical Oncology Next Generation Sequencing (NGS) Market Concentration Ratio (CR5 and HHI)
3.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players Head office and Area Served
3.3 Key Players Clinical Oncology Next Generation Sequencing (NGS) Product/Solution/Service
3.4 Date of Enter into Clinical Oncology Next Generation Sequencing (NGS) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type (2014-2019)
4.2 Global Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application (2014-2019)

5 United States
5.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
5.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in United States
5.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
5.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

6 Europe
6.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
6.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Europe
6.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
6.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

7 China
7.1 China Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
7.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in China
7.3 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
7.4 China Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

8 Japan
8.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
8.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Japan
8.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
8.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
9.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Southeast Asia
9.3 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
9.4 Southeast Asia Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

10 India
10.1 India Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
10.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in India
10.3 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
10.4 India Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

11 Central & South America
11.1 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size (2014-2019)
11.2 Clinical Oncology Next Generation Sequencing (NGS) Key Players in Central & South America
11.3 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Type
11.4 Central & South America Clinical Oncology Next Generation Sequencing (NGS) Market Size by Application

12 International Players Profiles
12.1 Illumina
12.1.1 Illumina Company Details
12.1.2 Company Description and Business Overview
12.1.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.1.4 Illumina Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.1.5 Illumina Recent Development
12.2 Roche
12.2.1 Roche Company Details
12.2.2 Company Description and Business Overview
12.2.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.2.4 Roche Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.2.5 Roche Recent Development
12.3 Agilent Technologies
12.3.1 Agilent Technologies Company Details
12.3.2 Company Description and Business Overview
12.3.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.3.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.3.5 Agilent Technologies Recent Development
12.4 Knome
12.4.1 Knome Company Details
12.4.2 Company Description and Business Overview
12.4.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.4.4 Knome Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.4.5 Knome Recent Development
12.5 Genomatix Software
12.5.1 Genomatix Software Company Details
12.5.2 Company Description and Business Overview
12.5.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.5.4 Genomatix Software Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.5.5 Genomatix Software Recent Development
12.6 GATC Biotech
12.6.1 GATC Biotech Company Details
12.6.2 Company Description and Business Overview
12.6.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.6.4 GATC Biotech Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.6.5 GATC Biotech Recent Development
12.7 Oxford Nanopore Technologies
12.7.1 Oxford Nanopore Technologies Company Details
12.7.2 Company Description and Business Overview
12.7.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.7.4 Oxford Nanopore Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.7.5 Oxford Nanopore Technologies Recent Development
12.8 Macrogen
12.8.1 Macrogen Company Details
12.8.2 Company Description and Business Overview
12.8.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.8.4 Macrogen Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.8.5 Macrogen Recent Development
12.9 Life Technologies
12.9.1 Life Technologies Company Details
12.9.2 Company Description and Business Overview
12.9.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.9.4 Life Technologies Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.9.5 Life Technologies Recent Development
12.10 DNASTAR
12.10.1 DNASTAR Company Details
12.10.2 Company Description and Business Overview
12.10.3 Clinical Oncology Next Generation Sequencing (NGS) Introduction
12.10.4 DNASTAR Revenue in Clinical Oncology Next Generation Sequencing (NGS) Business (2014-2019)
12.10.5 DNASTAR Recent Development
12.11 Exosome Diagnostics
12.12 Biomatters
12.13 CLC Bio
12.14 BGI
12.15 Qiagen
12.16 Perkin Elmer
12.17 Pacific Bioscience
12.18 Partek
12.19 GnuBIO
12.20 Foundation Medicine
12.21 Paradigm
12.22 Caris Life Sciences
12.23 Myriad Genetics

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details